Home > Insider Trading > Filing (0001819790-25-000097)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1819790	Tarsus Pharmaceuticals Inc.	TARS	Biological Products, (No Disgnostic Substances) (2836)	814717861

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1842190	Yeu Elizabeth Lin	C/O Tarsus Pharmaceuticals, Inc. 15440 Laguna Canyon Road, Suite 160 Irvine CA 92618	Chief Medical Officer	No	Yes	No	No

Transaction Summary

Sold:	1,006 shares	Avg. Price: $41.08	Total Value: $41,326.48
Number of Shares After Transactions:	7,694 shares

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2025-06-13	3,350	$0.00	8,700	No	4	M	Direct
Common Stock	Disposition	2025-06-16	1,006	$41.08	7,694	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2025-06-13	3,350	$0.00	3,350	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	15,866	Indirect	By Spouse's Roth IRA
Common Stock	12,040	Indirect	By 401(k) Plan

Footnotes

The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.
The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
Each RSU represents a contingent right to receive one share of the Company's common stock.
RSUs granted on June 13, 2024, in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.